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Edited by Hans-Dieter KlenkAbstract Neutralizing eﬀects of antibodies targeting the C-ter-
minal stalk (S2) subunit of the spike protein of severe acute
respiratory syndrome coronavirus have previously been reported,
although its mechanism remained elusive. In this study, high ti-
tered mouse antisera against the N-terminal globular (S1) and
S2 subunits of the S protein were generated and total immuno-
globulin G (IgG) was puriﬁed from these antisera. The eﬃciency
of these puriﬁed IgGs in virus neutralization and blocking of
receptor binding were compared quantitatively using virus neu-
tralization assay and a previously developed cell-based receptor
binding assay, respectively. We demonstrated that anti-S1 IgG
neutralizes the virus and binds to the membrane associated S
protein more eﬃciently than anti-S2 IgG does. Moreover, both
anti-S1 and anti-S2 IgGs were able to abolish the binding be-
tween S protein and its cellular receptor(s), although anti-S1
IgG showed a signiﬁcantly higher blocking eﬃciency. The unex-
pected blocking ability of anti-S2 IgG towards the receptor bind-
ing implied a possible role of the S2 subunit in virus docking
process and argues against the current hypothesis of viral entry.
On the other hand, the functional roles of the previously reported
neutralizing epitopes within S2 subunit were investigated using
an antigen speciﬁc antibody depletion assay. Depletion of anti-
bodies against these regions signiﬁcantly diminished, though
not completely abolished, the neutralizing eﬀects of anti-S2
IgG. It suggests the absence of a major neutralizing domain on
S2 protein. The possible ways of anti-S2 IgGs to abolish the
receptor binding and the factors restricting anti-S2 IgGs to neu-
tralize the virus are discussed.
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Severe acute respiratory syndrome (SARS) is an emerging
infectious disease caused by a zoonotic coronavirus (CoV)
named SARS-CoV [1]. The pandemic and re-emerging poten-
tial of the disease urged the development of eﬀective vaccines
against the virus. Based on the experiences in animal corona-
viral vaccines [2–4], the development of recombinant vaccines
against SARS-CoV was mainly focused on its spike (S) glyco-
protein [4,5]. The S protein of CoVs, which is classiﬁed as a
class I viral fusion protein, exists as radially protruded trimers
on the viral envelope and can be structurally or functionally
divided into two subunits, namely S1 and S2 subunits, repre-
senting the N-terminal globular head and the C-terminal mem-
brane-bound stalk, respectively [6,7]. The S1 subunit is
responsible for virus binding to cellular receptor(s) and con-
tains neutralizing epitopes. The S2 subunit mediates mem-
brane fusion during viral infection and is believed to be
unable to induce neutralizing antibody in a number of CoVs
[8–11].
On the contrary, several reports suggested that the S2 subunit
of SARS-CoV contains neutralizing epitopes of the virus.
Immunization of either Escherichia coli expressed or chemically
synthesized S2 peptides elicited neutralizing antibody [12–14]
or speciﬁc antibody responses [15,16] in animal models. More-
over, neutralizing epitopes were mapped on the S2 subunit by
biopanning of phage display dodecapeptide library with anti-
sera from convalescent SARS patients [17] or by screening anti-
body-phage display library constructed with B-cells of
convalescent SARS patients [18]. Immunization of plasmids
encoding the S2 subunit, which may better mimic its native
antigenic properties, was reported to induce neutralizing anti-
bodies in rabbits [19]. Our earlier study [20] also demonstrated
the cooperative neutralizing eﬀect of anti-S1 and anti-S2
antibodies from mice immunized with plasmids encoding
S1 and S2 subunits. These results suggest the presence of
neutralizing epitopes within the S2 subunit of SARS-CoV,ation of European Biochemical Societies.
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[8].
The mechanism of the eﬃcient neutralizing eﬀect of anti-S1
antibodies is logically proposed as prevention of spike-to-recep-
tor engagement event by blocking of its receptor binding
domain [5]. However, the mechanisms involved in the neutral-
ization mediated by anti-S2 antibodies remain to be clariﬁed.
As a class I viral fusion protein, the S2 subunit of corona-
viruses has its typical functional domains [21], including a
fusion peptide [22], heptad repeats (HR), aromatic amino acids
cluster [23] and transmembrane domain. Blocking the actions
involving these domains may prevent the virus from entering
its host cell, although this concept remains to be proven exper-
imentally. Neutralizing antibody against the S2 subunit of
mouse hepatitis virus was reported to bind to a determinant
of nine amino acids near the fusion peptide, preventing fusion
activity during virus entry [24]. Lip and colleagues [25] demon-
strated that monoclonal antibodies targeting the regions both
within and immediately after the C-terminal HR (C-HR) do-
main are able to neutralize SARS-CoV and inhibit cell–cell
membrane fusion, implying blocking of membrane fusion may
be a possible neutralizing mechanism of anti-S2 antibodies.
Recent advances in epitopemapping of gp41 of human immuno-
deﬁciency virus (HIV), which is a membrane anchoring subunit
of class I viral fusion proteins and the counterpart of SARS-
CoV S2 subunit, identiﬁed several neutralizing epitopes that
are proximal to the viral membrane but not near fusion peptide
[26–28]. Although the mechanism of neutralization through
these epitopes on gp41 of HIV is not well understood, these re-
sults suggest that antibodies targeting the membrane anchoring
subunit of a class I viral fusion protein, e.g. S2 subunit of SARS-
CoV, may also eﬃciently interfere the virus entry into host cells.
Although the neutralizing eﬀects of anti-S1 and anti-S2 anti-
bodies to coronaviruses have been widely characterized, they
were not compared quantitatively and the neutralizing mecha-
nisms of anti-S2 antibodies are still unclear. In this study, we
immunized mice with plasmids and recombinant adenoviruses
(rAds) encoding the S1 and S2 subunits of SARS-CoV. Virus
neutralization eﬃciency of puriﬁed anti-S1 and anti-S2 IgGs,
as well as their binding ability towards, membrane associated
S (m-S) protein, i.e. S protein anchored on cell membrane that
resembles its native structure, were compared quantitatively.
In addition, using a cell-based receptor binding assay, we also
showed that the anti-S2 antibodies are able to abolish the bind-
ing between m-S and the cellular receptors, providing possible
new clues towards the understanding of the neutralizing mech-
anisms of anti-S2 antibodies.2. Materials and methods
2.1. Cell culture, plasmids and viral vectors
Mammalian cell lines, including AD293 (Stratagene), Vero E6
[American Type Culture Collection (ATCC), CRL-1586], FRhK4
(ATCC, CRL-1688) and BHK21 (ATCC, CCL-10), and a chicken
embryonic ﬁbroblast cell line, DF1 (ATCC, CRL-12203), were propa-
gated and maintained according to the manufacturers’ instructions.
Recombinant adenoviruses encoding the full length S protein (aa 1-
1255) of SARS-CoV and green ﬂuorescent protein (GFP), designated
as rAd-S and rAd-GFP respectively, were constructed as described pre-
viously [29] and used for in vitro expression. Mammalian expression
plasmids and rAds encoding the S1 subunit (aa 18–683), S2 subunit
(aa 684–1255) and nucleocapsid (N) protein (aa 1–422) of SARS-
CoV, designated as pCI-sp-S1, pCI-sp-S2 and pCI-N for the plasmidsor rAd-S1, rAd-S2 and rAd-N for the rAds, respectively, were con-
structed as described previously [20,29]. A recombinant modiﬁed vac-
cinia virus Ankara (rMVA) encoding both the full length S (aa 1–1255)
of SARS-CoV and a GFP marker (rMVA-S/GFP), which was used for
in vitro expression, was kindly provided by professor B. Moss [30] at
National Institute of Allergy and Infectious Diseases, NIH, USA. It
is noted that the amino acid residues of viral genes in this study are
numbered with reference to SARS-CoV strain HKU-39849 [31].2.2. Immunization of mice and total IgG puriﬁcation
Two groups of 20 BALB/c mice aged 6–8 weeks were immunized
intramuscularly with plasmid DNA (100 lg per dose), including pCI-
sp-S1 and pCI-sp-S2 respectively, for three doses at interval of three
weeks. Sixth week after the last dose of DNA immunization, these
two groups of mice were boosted with rAds encoding the correspond-
ing antigens intraperitoneally, i.e. rAd-S1 and rAd-S2, at 5 · 108 pla-
que forming units per dose. A control group was immunized at the
same dose and schedule except pCI-N and rAd-N were used. Serum
samples of all mice groups were collected at one, two, three and four
weeks after the rAd booster. The antisera collected from diﬀerent time
points of each mice group were pooled and stored at 20 C until use.
The SARS-CoV speciﬁc antibody titers of the collected antisera were
evaluated by using human anti-SARS-CoV antibody (IgG) ELISA
kit (Beijing Huada GBI Biotechnology, Beijing China) according to
the manufacturer’s instructions, except that HRP-conjugated anti-
mouse IgG (H + L) (Zymed) was used as the secondary antibody.
Total IgG was puriﬁed from the collected antisera by mouse IgG puri-
ﬁcation kit (Aﬃ-Gel Protein A MAPS II Kit, BIO-RAD) according to
the manufacturer’s instructions. The puriﬁed IgGs were quantiﬁed
with anti-mouse IgG assay plates (Becton Dickinson) according to
the manufacturer’s instructions, with mouse IgG (PharMingen) as
the standard and HRP-conjugated anti-mouse IgG (H + L) as the
secondary antibody.2.3. Virus neutralization assay
The puriﬁed IgG samples were diluted using normal mouse serum to
the indicated concentrations (2–20 mg/ml). The neutralizing eﬀect of
each diluted IgG sample was evaluated using virus neutralization assay
as described previously [20], with 100 TCID50 of SARS-CoV strain
HKU-39849 [31] were used for each well in a 96-well plate.
2.4. Binding eﬃciency of anti-S1 and anti-S2 antibodies to m-S protein
AD293 cells expressing m-S protein (AD293-S cells) were prepared
by transducing AD293 cells with rAd-S according to the procedures
described by Chow et al. [29]. The AD293-S cells were harvested and
washed with FACS buﬀer (phosphate-buﬀered saline (PBS) containing
4% fetal bovine serum (FBS)). To demonstrate the m-S protein binding
ability of anti-S1 and anti-S2 antibodies, 50 ll of FACS buﬀer contain-
ing the puriﬁed IgG samples was used to resuspend 2 · 105 of AD293-S
and kept on ice for 30 min. After washing three times with ice-cold
FACS buﬀer, the IgG-incubated AD293-S was resuspended in goat
anti-mouse IgG (H + L)-FITC (Zymed) and kept on ice for 30 min.
The mean ﬂuorescent intensity (MFI) of these AD293-S cells, which
is positively related to the amount of bound mouse IgG, is evaluated
by counting 1 · 104 cells in each of the samples using Coulter Epics
Elite Flow Cytometer. The experiment was performed in triplicate
and the data was analyzed with the WinMDI 2.81 (Scripps Research
Institute). The average of MFI of the triplicates was presented with
standard deviations (S.D.).
To further compare the m-S binding eﬃciency of anti-S1 and anti-S2
IgGs, a serial antibody binding and depleting assay was carried out. In
this assay, approximately 5 · 105 AD293-S cells were incubated with
100 ll of FACS buﬀer containing 1.6 mg/ml of the puriﬁed IgG samples
on ice for 20 min to allow antibody binding. The anti-S1, anti-S2 and
anti-N IgG bound AD293-S cells, designated as anti-S1/, anti-S2/ and
anti-N/AD293-S respectively, were spun down at 1000 · g for 2 min
to deplete the bound antibody from the liquid phase and the superna-
tant, i.e. FACS buﬀer containing the unbound IgG, was transferred
to a new tube containing 5 · 105 AD293-S cells for the next round of
binding and depleting under the same condition. The concentration
of the unbound IgG after each depletion round was monitored by ana-
lyzing 0.5 ll of the supernatant using the anti-mouse IgG quantiﬁcation
assay as described. The IgG bound AD293-S cell pellet was washed
three times with FACS buﬀer and analyzed using ﬂow cytometer after
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repeated 20 times in triplicate and the average MFI of the triplicates
for each depletion round were recorded.2.5. Cell-based receptor binding assay
To evaluate the ability of puriﬁed IgG samples to block the m-S pro-
tein from binding with its cellular receptor, a cell-based receptor bind-
ing assay was carried out as described by Chou et al. [32] with
modiﬁcations. Brieﬂy, three types of ligand cells were prepared, includ-
ing AD293 transduced with both rAd-S and rAd-GFP (AD293-S/
GFP), and two other line cells, BHK21 and DF1, infected with
rMVA-S/GFP (BHK21-S/GFP and DF1-S/GFP). A control ligand cell
was also prepared from AD293 transduced with rAd-GFP only
(AD293-GFP). The receptor-expressing cells, i.e. Vero E6 monolayer,
were prepared in six-well plates with 100% conﬂuence. The puriﬁed
IgG samples were diluted with FACS buﬀer to the indicated concentra-
tions and 2 · 105 ligand cells were pre-incubated with 50 ll of each di-
luted IgG at 4 C for 30 min. The ligand cells together with the IgG
samples were laid on Vero E6 monolayer for binding and the unbound
ligand cells were washed away according to the procedures described
by Chou et al. [32]. The bound ligand and Vero E6 cells were detached
by trypsin and ﬁxed in 2% of paraformaldehyde in PBS. The number
of bound ligand cells in each sample was then counted with ﬂow
cytometer and the mean values from triplicates were recorded.
To compare the blocking eﬃciency between anti-S1 and anti-S2
IgGs, only AD293-S/GFP was used as the ligand cell and the blocking
eﬃciency was deﬁned as (Nunblock  Nblock)/(Nunblock  Nbackground) ·
100%, where Nblock and Nunblock represent the number of bound ligand
cells, i.e. AD293-S/GFP, with and without IgG pre-incubation respec-
tively, and Nbackground is the number of bound control ligand cells, i.e.
AD293-GFP.2.6. Antigen speciﬁc antibody depletion assay
Regions within or proximal to the fusion peptide and the C-HR of
the S2 subunit have been reported to contain neutralizing epitopes
(Fig. 1). To investigate the functional roles of these epitopes, E. coli ex-
pressed peptides covering these regions were used to deplete antibodies
against the linear epitopes within these regions in the puriﬁed anti-S2
IgG. Two regions covering aa 787–828 and aa 1023–1131, with refer-
ence to strain HKU-39849 [31], were PCR ampliﬁed and fused using
overlapping extension PCR. The fused coding sequence, designated
as S2-Ept, was cloned into pRSET-A (Invitrogen), sequenced and then
expressed in E. coli strain BL-21 (Invitrogen) according to the manu-
facturer’s instructions. The expressed peptide was aﬃnity puriﬁed
through its N-terminal fused histidine tag (His-tag) with Ni2+ charged
agarose (Milli-Pore) and its identity was conﬁrmed by Western blots
with AP-conjugated anti-His-tag antibody (Invitrogen) according to
the manufacturer’s instructions. The puriﬁed peptide was incubated
with 50 ll of anti-S2 IgG (3.2 mg/ml) at 4 C for 2 h. The IgG bound
peptide complexes and unbound peptides were then removed using
His-tag aﬃnity puriﬁcation. The peptide–IgG mixture was allowed
to pass through the Ni2+-agarose column three times and the ﬂow-
through, which represents the S2-Ept bound IgG depleted anti-S2
IgG, designated as dep-anti-S2 IgG, were collected and subjected to
virus neutralization and IgG quantiﬁcation ELISA as described. Three
control depletions, including anti-S1 IgG with or without addition ofFig. 1. Schematic diagram of S2 functional domains and regions
containing neutralizing epitopes. The black boxes, white boxes and
black lines represent the S2 functional domains, regions chosen for this
study (designated as S2-Ept) and regions containing previously reported
neutralizing epitopes, respectively. The number of the references of the
reported neutralizing regions is listed on the right column. FP, N-HR,
C-HR and T refer to fusion peptide, N-terminal and C-terminal heptad
repeat, and transmembrane domain respectively.S2-Ept peptide (designated as dep-anti-S1 IgG and mock depleted
anti-S1 IgG, respectively), and anti-S2 without addition of S2-Ept pep-
tide (i.e. mock depletion), were performed to evaluate the speciﬁcity
the depletion process and its possible artifacts in virus neutralization.
The speciﬁc binding between anti-S2 IgG and S2-Ept peptide was con-
ﬁrmed by Western blots.
2.7. Statistical analysis
A student’s t-test was used to compare the signiﬁcance between spec-
iﬁed groups, with P 6 0.05, or 0.01 be deﬁned as statistically signiﬁ-
cant.3. Results
3.1. Neutralizing eﬃciency and additive neutralizing eﬀect of
anti-S1 and anti-S2 antibodies
With plasmid DNA prime and viral vector boost immuniza-
tion regimen, SARS-CoV speciﬁc antibodies of much higher
titer were observed when compared to that of our previous
study, which employed plasmid DNA immunization only
[20]. Mice immunized with recombinant vaccines encoding
S1 subunit generally showed higher neutralizing titer against
SARS-CoV in their antisera than those immunized with S2
antigens (data not shown). In order to quantitatively compare
the neutralizing eﬃciency of anti-S1 and anti-S2 antibodies,
puriﬁed anti-S1 or anti-S2 total IgGs with the same concentra-
tion range were subjected to virus neutralization assay. The
negative control, i.e. anti-N IgG, was also puriﬁed and sub-
jected to virus neutralization assay, which showed no neutral-
izing eﬀect in all tested concentrations. The neutralizing
eﬃciency of anti-S1 and anti-S2 IgGs, which is generally
deﬁned as the increment of neutralizing titer with increasing
concentration of IgG, or simply as the slopes of the plots in
Fig. 2A, was compared. Fig. 2A demonstrates that both
anti-S1 and anti-S2 IgG neutralized SARS-CoV in a wide
range of concentrations and the neutralizing eﬃciency of
anti-S1 IgG is approximately 2.3 times higher than that of
anti-S2 IgG (Slopanti-S1/Slopanti-S2) in the tested IgG concentra-
tions.
Our previous results suggested that anti-S1 and anti-S2 anti-
bodies cooperatively neutralize SARS-CoV [20]. To further
investigate this phenomenon, anti-S2 IgG at ﬁnal concentra-
tion of 4, 8 and 16 mg/ml were subjected to neutralization as-
says alone or mixed with anti-S1 IgG at a ﬁnal concentration
of 2 or 0.5 mg/ml. Additive neutralizing eﬀects, i.e. enhance-
ment of neutralizing titer when anti-S1 IgG is added, were
observed in anti-S2 IgG at concentration of 4 and 8 mg/ml,
although at high concentration of anti-S2 IgG (16 mg/ml),
the addition of anti-S1 IgG only provided little further increase
in virus neutralizing titer (Fig. 2B). Present results demon-
strated that both anti-S1 and anti-S2 IgGs were able to neu-
tralize SARS-CoV with diﬀerent eﬃciency and additive
neutralizing eﬀects of these antibodies were observed at a rel-
atively low concentration.
3.2. The binding eﬃciency of anti-S1 and anti-S2 antibodies to
m-S protein
Fig. 3A demonstrates that both anti-S1 and anti-S2 IgGs
were able to bind speciﬁcally with AD293-S cells, while the
anti-N control IgG shows no signiﬁcant binding. All IgGs
showed no signiﬁcant binding toward non-transduced AD293
(data not shown), demonstrating the speciﬁcity of the binding
Fig. 2. The neutralizing eﬃciency and additive neutralizing eﬀect of anti-S1 and anti-S2 IgG. (A) The geometric mean neutralizing titers of anti-S1
and anti-S2 IgGs of the same concentration range, i.e. 2–20 mg/ml, were compared. The values of y-axis are showed in logarithmic scale and the
dotted lines represent the best-ﬁt line obtained from linear regression of the datasets. Data of Anti-N IgG is not shown since it did not show any
neutralizing eﬀect in all tested concentrations. (B) The geometric mean neutralizing titers of anti-S2 IgG of diﬀerent concentrations mixed with 0.5 or
2 mg/ml of anti-S1 IgG. The average values of the triplicates were indicated and the error bars represent the SD of the triplicates. The geometric mean
neutralizing titers of 0.5 and 2 mg/ml of anti-S1 IgG are 29.6 (S.D. = 3.8) and 51.3 (S.D. = 11.8), respectively.
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binding capacity of m-S protein towards anti-S1 IgG, i.e. the
amount of anti-S1 IgG bound to m-S protein, is substantially
larger than that of anti-S2 IgG under the same tested concen-
trations, i.e. 3.2 and 0.8 mg/ml (Fig. 3A). The diﬀerential bind-
ing of both IgGs to m-S was further demonstrated with
diﬀerent IgG dosages. The binding eﬃciency to m-S, i.e. the
increment of MFI with increasing concentration of IgG, be-
tween anti-S1 and anti-S2 IgG was very diﬀerent in the tested
range of IgG concentrations (Fig. 3B).
To investigate the observed diﬀerences between the binding
capacities of m-S protein towards anti-S1 and anti-S2 IgGs,
a serial antibody binding and depleting assay, was performed
and the results are shown in Fig. 3C. The behaviors of anti-
S1 and anti-S2 IgGs are strikingly diﬀerent in this assay.
Firstly, the MFI of anti-S1/AD293-S cells drops more than
50% of its starting MFI after the ﬁrst 5 depletion rounds
and slowly decreases after each of the last 15 depletion rounds,
while no considerable decrement is observed in the MFI of
anti-S2/AD293-S cells even after 20 rounds of depletion
(Fig. 3C, upper panel). Secondly, the absolute amounts of both
the unbound anti-S1 and anti-S2 IgGs decrease during the
depletion rounds but the decrement of the unbound anti-S1
is substantially larger than that of the unbound anti-S2 IgG
after each depletion round (Fig. 3C, lower panel). It is also
noted that the MFI of anti-N/AD293-S cells is signiﬁcantly
lower than that of anti-S1/ and anti-S2/AD293-S cells during
the depletion rounds, and the absolute amount of anti-S1
and anit-S2 IgG is depleted at a considerably higher rate than
that of anti-N IgG, demonstrating the depletion of IgG is S
protein speciﬁc. These observations imply that: (1) anti-S1
IgG has a good binding capacity to m-S and therefore can
be eﬃciently removed from the IgG pool after every binding-
depleting cycle; and (2) binding of anti-S2 IgG to m-S protein,
however, is restricted and hence the dynamic change of free
anti-S2 IgG is diﬀerent from that of anti-S1 and anti-N IgG
in the process of depletion, characterized by a limited amount
of anti-S2 IgG bound and removed in each depletion cycle and
an abundant free IgG sustained a close value of MFI even after
many round of depletion.3.3. Abolition of receptor binding by anti-S2 IgG in cell-based
receptor binding assay
In the cell-based receptor binding assay, we found that not
only anti-S1 IgG, but also anti-S2 IgG abolished the binding
between the ligand cells, i.e. AD293-S/GFP and the receptor
expressing cells, i.e. Vero E6, while the control anti-N IgG
did not (Fig. 4A). Since the abolition of receptor binding to
m-S protein by anti-S2 IgG is not reported previously, we fur-
ther conﬁrmed this phenomenon by repeating the binding
assay with other ligand cells. Fig. 4B demonstrates that anti-
S2 IgG is able to abolish the binding of BHK21-S/GFP or
DF1-S/GFP to Vero E6 cells with diﬀerent eﬃciencies, indicat-
ing that the abolition of receptor binding is speciﬁc to S pro-
tein and independent of ligand cell types.
In order to quantitatively compare the performance of anti-
S1 and anti-S2 IgGs in abolition of receptor binding, their
blocking eﬃciency were evaluated in a wide range of IgG con-
centration (Fig. 4C). Remarkably, anti-S1 IgG was able to
abolish the receptor binding at a relatively low concentration
(<0.01 mg/ml) while anti-S2 IgG did not. Moreover, the block-
ing eﬃciency of anti-S1 IgG was generally higher than that of
anti-S2 IgG under the same tested concentration, although
both IgGs showed complete blocking of receptor binding at
about 10 mg/ml (Fig. 4C). The above data indicated that both
anti-S1 and anti-S2 IgGs are able to speciﬁcally abolish the
binding between m-S protein and the receptor(s) on Vero E6
cells, while anti-S1 IgG abolishes the binding more eﬃciently
than anti-S2 IgG does under the same tested conditions.
3.4. The role of S2-Ept in virus neutralization
To investigate the contribution of two speciﬁc regions on the
S2 subunit, i.e. S2-Ept (Fig. 1), to the elicitation of neutralizing
antibody by S2 subunit expressed in vivo, antibodies against
the epitopes of S2-Ept in anti-S2 IgG were depleted by
E. coli expressed peptide covering these regions. The speciﬁc
binding between the S2-Ept peptide and anti-S2 IgG is demon-
strated in Fig. 5A. The neutralizing titer of dep-anti-S2 IgG
was found to decrease signiﬁcantly (P < 0.05, ) at various pep-
tide concentrations. Such IgG depletion is demonstrated to be
S2 speciﬁc as no signiﬁcant decrease of neutralizing titer was
Fig. 3. The binding eﬃciency of anti-S1 and anti-S2 IgGs towards m-S protein. (A) Flow cytometry showing that anti-S1 and anti-S2 IgGs
speciﬁcally bind to m-S protein on AD293 cells. The shaded peaks represent the background signal, i.e. cells without IgG incubation, and the non-
shaded peaks represent cells incubated with 0.8 (upper panel) or 3.2 (lower panel) mg/ml of anti-N, anti-S1 and anti-S2 IgG as indicated. (B) Anti-S1
IgG binds more eﬃciently to m-S protein than anti-S2 IgG does. The error bars represent the SD of the triplicates. (C) The results of the serial
antibody binding and depleting assay. The upper and lower panels show the decrement of MFI and percentage of remaining IgG after each round of
depletion, respectively. Each data point represents the average value of three triplicates.
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IgG (data not shown). It is noted that antibodies against epi-
topes in S2-Ept was undetectable in dep-anti-S2 IgG but
detectable in the mock depleted anti-S2 IgG using Western
blots (data not shown), demonstrating that only a negligible
amount of anti-S2-Ept antibodies is present in dep-anti-S2
IgG. In addition, according to the IgG quantiﬁcation ELISA,
no signiﬁcant loss of total IgG was observed between the
dep-anti-S2 IgG and the mock depleted anti-S2 IgG (data
not shown) and indicating that the IgG against S2-Ept only
contributes a negligible fraction of the total anti-S2 IgG popu-
lation although it contributes signiﬁcantly to virus neutraliza-
tion. On the other hand, the blocking eﬃciency of mockdepleted anti-S2 IgG and dep-anti-S2 IgG in the cell-based
receptor binding assay were not signiﬁcantly diﬀerent (data
not shown), implying anti-S2-Ept IgG may not play a major
role in the blocking of receptor binding.4. Discussion
While the neutralizing eﬀect of anti-S1 antibodies in most of
the human and animal CoVs is well established, the contribu-
tion of anti-S2 antibodies to virus neutralization remains
controversial. This was mainly reported for SARS-CoV and
even in our earlier studies [20] we failed to prove that anti-S2
Fig. 4. Abolition of receptor binding by anti-S1 and anti-S2 IgGs in cell-based receptor binding assay. (A) The abolition of receptor binding by anti-
S1 and anti-S2 IgGs is speciﬁc. Ligand cells, i.e. AD293-S/GFP, incubated with anti-S1 and anti-S2 IgGs showed a substantially smaller number of
bound cells (green ﬂuorescent spots) when compared with those incubated with anti-N IgG or no IgG incubation. The images shown are
representative views (magniﬁcation of 100·) of each treatment as indicated. (B) Abolition of receptor binding of diﬀerent types of ligand cells by anti-
S2 IgGs. The signiﬁcance of diﬀerences between the numbers of bound cells of the control IgG, i.e. anti-N IgG, and anti-S1 or anti-S2 IgG is
represented by asterisks (P < 0.01,  or P < 0.05, ). The results are presented in average of the triplicates with S.D. The types of ligand cells used are
indicated at the top of each data group. (C) The blocking eﬃciency of anti-S1 IgG is higher than that of anti-S2 IgG under the same concentrations
tested. Each data point represents the average value of three replicates. The x-axis, i.e. IgG concentration, is presented in logarithmic scale.
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bodies. This was probably due to the low titer of the antisera
used. In this study, high titered anti-S1 and anti-S2 antibodies
were generated with DNA-prime-viral-booster immunization
regimen in mice, allowing us to characterize the roles of the S1
and S2 subunits in virus docking and virus neutralization. Here,
we demonstrated both anti-S1 and anti-S2 IgGs are able to neu-
tralize the virus with signiﬁcant diﬀerence in eﬃcacy (Fig. 2A),
which were not compared quantitatively in previous studies of
other CoVs or other class I virus fusion proteins. In addition,
the observed diﬀerences of neutralizing eﬃcacies may be ac-
counted, at least partially, by the antibody binding to m-S assay
(Fig. 3), in which we showed that the binding capacities of m-S
protein for anti-S1 IgG is signiﬁcantly larger than that of anti-S2
IgG. The low antibody binding capacity of the S2 subunit
(Fig. 3C) may be explained by the limited accessible surface
for anti-S2 IgG, as it has a coiled-coil trimeric structure forming
a compact short stalk which is hided under the globular S1 sub-
unit and radially covered by oligosaccharides [33]. A similar
ﬁnding on the steric constraints for antibody to access gp41, an-
other class I virus fusion protein of HIV, was reported and dis-
cussed recently [34,35].Despite the widely reported neutralizing epitopes within the
S2 subunit, the role of anti-S2 antibodies in virus neutraliza-
tion remains unknown. Based on the existing viral entry model
of CoVs [7], it is proposed that the virus docks to host cell sur-
face through the binding between the globular S1 subunit and
cellular receptor(s), then the stalk-like S2 subunit undergoes
structural changes to initiate the fusion between viral envelope
and host cell membrane, allowing the migration of the viral
nucleocapsid into the cytosol. According to the previous stud-
ies of class I virus fusion proteins in other viruses [21,36,37],
immediately after the receptor binding of their globular do-
mains, the six-helix bundled HR regions of their membrane fu-
sion subunits, i.e. S2 subunit in the case SARS-CoV, undergo
dramatic conformational transition to expose its hydrophobic
fusion peptide and mediates the subsequent virus–cell fusion.
However, no evidence was reported to relate these structural
changes to the attachment and docking of these viruses. Inter-
estingly, in our study, anti-S2 antibodies were demonstrated to
be able to abolish the binding between S protein and its host
cell in the cell-based receptor binding assay, implying the pos-
sible involvement of the S2 subunit in virus docking process.
The unanticipated blocking ability of anti-S2 antibodies argues
Fig. 5. The role of S2-Ept in virus neutralization. (A) Identiﬁcation of
S2-Ept peptide using Western blot. (B) The neutralizing titer of S2-Ept
depleted anti-S2 IgG is lower than the mock depleted anti-S2 IgG
(0 mg/ml). The results were presented as the average of geometric mean
of neutralizing titer of three replicates and the error bar represents its
SD. The statistical signiﬁcance of diﬀerences between the geometric
mean of neutralizing titer of dep-anti-S2 IgG and mock depleted anti-
S2 IgG is represented by an asterisk (P < 0.05, ). It is noted that no
signiﬁcant decrease of neutralizing titer was observed between dep-
anti-S1 IgG and mock depleted anti-S1 IgG (data not shown).
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membrane fusion but not virus docking. Therefore, we pro-
pose that successful docking or attachment of SARS-CoV
may not solely rely on the receptor binding of S1 subunit
but may also depend on actions involving the S2 subunit,
which therefore can be blocked by anti-S2 IgG. To this end,
we hypothesize two possible mechanisms to explain this obser-
vation. Firstly, we propose that the S2 subunit may participate
in a global structural change of the spike which strengthens the
binding or enhance the surface complementariness [38] be-
tween the receptor binding domain and its receptor. Alterna-
tively speaking, the bound anti-S2 antibodies may stress the
S1 subunit and prevent the receptor binding domain from
forming a complementary surface with its receptor [38]. Sec-
ondly, binding between the S1 subunit and host receptor(s)
may be reversible and the virus may fail to stably dock to
the host cell surface without subsequent insertion of the fusion
peptide into the host cell membrane. One other possible expla-
nation is simply the bulkiness of the bound anti-S2 antibodies
may hinder the spike from binding with its receptor.
Currently, the neutralizing epitopes of S2 subunit are mainly
mapped to regions proximal to the fusion peptide and the C-
HR (Fig. 1). In addition, neutralizing antibodies targeting
one of these regions have been found in sera of recovered
SARS patients [17]. Using antigen speciﬁc antibody depletionassay, we demonstrated that the existence of neutralizing deter-
minants within these regions as depletion of antibodies against
these regions signiﬁcantly diminished the neutralizing eﬀects of
anti-S2 IgG (Fig. 5B). However, the residual neutralizing eﬀect
of the dep-anti-S2 IgG implies these regions may not be the
sole neutralizing determinants and suggests the presence of
neutralizing epitopes within other regions of the S2 subunit,
such as the recent report on monoclonal neutralizing antibody
targeting the C-HR [13,25]. It is noted that a similar depletion
assay has been used to prove the existence neutralizing epi-
topes beyond the receptor binding domain of the SARS S1
subunit [39]. Furthermore, the blocking eﬃciency of dep-
anti-S2 IgG was comparable to that of the mock depleted
anti-S2 IgG, indicating these regions may not be involved in
virus docking, and alternatively speaking, the neutralizing
mechanism of these epitopes may not involve blocking of
receptor binding. On the other hand, some neutralizing epi-
topes may only be exposed during the conformational change
of S2 protein triggered by receptor binding since binding of
anti-S2 IgG to m-S is nearly saturated in low range of IgG con-
centrations (Fig. 3B) but such saturation was not observed in
neutralizing assay (Fig. 2A) and cell-based receptor binding as-
says (Fig. 4C). Although currently no neutralizing epitope was
mapped to the C-terminal tail of the S2 subunit of SARS-CoV,
neutralizing epitopes were mapped on the corresponding re-
gion of gp41 [40], implying the presence of possible functional
roles of the regions other than the deﬁned functional domains
(e.g. HR and fusion peptide) in class I virus fusion proteins.
The present experimental data suggests that there is no major
neutralizing domain, like receptor binding domain of S1, on S2
protein.
In conclusion, the eﬃciency of anti-S1 and anti-S2 IgGs in
virus neutralizing, S protein binding and blocking of receptor
binding were compared quantitatively in this study. Although
anti-S2 IgG neutralizes the virus less eﬃciently as compared
with the anti-S1 IgG, the sequence conservation of S2 subunit
across various strains, including the SARS-like CoV in civet
[41] and bats [42,43], and its additive neutralizing eﬀects with
anti-S1 antibody still make it a candidate for development of
recombinant vaccines if the neutralizing eﬃciency can be
greatly improved. Taken together with the results of the quan-
titative comparisons and the antigen speciﬁc antibody deple-
tion assay, this study puts toward new understanding of the
functional roles of the S2 subunit, hence the neutralizing mech-
anisms of anti-S2 antibodies, which would certainly provide
valuable information for rational design of vaccines or anti-
body therapeutics against the virus.Conﬂict of interest statement
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